2
项与 CD33/CLL1 dual CAR-NK cells(Hangzhou Qihan Biotech) 相关的临床试验Clinical Study to Evaluate the Safety and Efficacy of iPSC -NK Cells Targeting CLL1 or CD33 in Patients With Relapsed/Refractory AML
This is a phase 1, first-in-human (FIH), open-label, multicohort study to evaluate the safety, tolerability and preliminary efficacy of CLL1 or CD33 target Chimeric antigen receptor (CAR) -induced pluripotent stem cells derived NK cells in patients with relapsed/refractory AML
/ Not yet recruiting临床1期IIT Phase I Study to Evaluate the Safety and Efficacy of NK Cell Therapy in Acute Myeloid Leukemia (AML).
This is a phase 1, first-in-human (FIH), open-label, multicohort study to evaluate the safety, tolerability and preliminary efficacy of iPSC NK cells in patients with relapsed/refractory AML or AML Minimal Residual Disease (MRD).
100 项与 CD33/CLL1 dual CAR-NK cells(Hangzhou Qihan Biotech) 相关的临床结果
100 项与 CD33/CLL1 dual CAR-NK cells(Hangzhou Qihan Biotech) 相关的转化医学
100 项与 CD33/CLL1 dual CAR-NK cells(Hangzhou Qihan Biotech) 相关的专利(医药)
100 项与 CD33/CLL1 dual CAR-NK cells(Hangzhou Qihan Biotech) 相关的药物交易